News

Achieve Life Sciences Follow 1,694 504

Achieve's focus is to address the global smoking health epidemic, which is currently the leading cause of preventable death.

achievelifesci
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
11 Feb 1889313071874662449

You’re invited! Join CEO, Rick Stewart, at 10am ET this morning for a virtual presentation at the @Oppenheimer 35th Annual Healthcare Life Sciences Conference: ...http://bit.ly/Achieve-webcast

Learn more about our ambition at http://AchieveLifeSciences.com.

Reply on Twitter 1889313071874662449 Retweet on Twitter 1889313071874662449 1 Like on Twitter 1889313071874662449 4 Twitter 1889313071874662449
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
10 Feb 1888944797865443383

The Data Safety Monitoring Committee has completed its 2nd review of the ORCA-OL trial, confirming no new safety concerns. The review puts us one step closer to realizing the ...potential to help millions of people to quit smoking and vaping.

Learn more: http://bit.ly/ORCA-DSMC

Reply on Twitter 1888944797865443383 Retweet on Twitter 1888944797865443383 1 Like on Twitter 1888944797865443383 2 Twitter 1888944797865443383
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
10 Jan 1877710019489107970

Today we welcome Dr. Kristen Slaoui and Nancy Phelan to Achieve’s Board of Directors. Their expertise in driving business growth and healthcare innovation will be key as we ...continue to shape the future of smoking cessation treatment.

Learn more: http://bit.ly/BOD-announcement

Reply on Twitter 1877710019489107970 Retweet on Twitter 1877710019489107970 0 Like on Twitter 1877710019489107970 2 Twitter 1877710019489107970
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
7 Jan 1876622868743627007

Our ongoing ORCA-OL clinical trial has officially reached the long-term exposure requirement for NDA submission, which is on track for Q2 2025. We continue to evaluate longer-term... safety in adults struggling with nicotine dependence. Read more: http://bit.ly/ORCA-OL

Reply on Twitter 1876622868743627007 Retweet on Twitter 1876622868743627007 0 Like on Twitter 1876622868743627007 2 Twitter 1876622868743627007
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
6 Jan 1876263518003159170

Join us next week at #JPM2025! Our team will sharing the latest innovation in smoking cessation research and how we hope to transform the treatment landscape for nicotine ...dependence. Let’s discuss how we can help shape a healthier, nicotine-free future!

Reply on Twitter 1876263518003159170 Retweet on Twitter 1876263518003159170 0 Like on Twitter 1876263518003159170 1 Twitter 1876263518003159170
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
30 Dec 1873776065019338992

The countdown to 2025 is on! Now is the perfect time to start the year with healthy resolutions and embrace a #smokefree future.

#SmokingCessation #QuitSmoking #Nicotine #Smokers... #NewYearsResolution

Reply on Twitter 1873776065019338992 Retweet on Twitter 1873776065019338992 2 Like on Twitter 1873776065019338992 5 Twitter 1873776065019338992
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
23 Dec 1871224249056465379

$ACHV wishes you and your loved ones a wonderful holiday season! As we reflect on the year, we’re proud of the progress made in the fight against nicotine dependence and remain ...committed to supporting a smoke-free future for all.

#SmokingCessation #QuitSmoking #Nicotine #Smokers

Reply on Twitter 1871224249056465379 Retweet on Twitter 1871224249056465379 0 Like on Twitter 1871224249056465379 2 Twitter 1871224249056465379
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
18 Dec 1869389659777667539

We're reflecting on some of our 2024 key milestones: The FDA granted Breakthrough Therapy Designation for cytisinicline, Phase 2 ORCA-V1 study was published in @JAMAInternalMed, ...and we completed enrollment in the ORCA-OL Clinical Trial. Learn more: http://achievelifesciences.com

Reply on Twitter 1869389659777667539 Retweet on Twitter 1869389659777667539 1 Like on Twitter 1869389659777667539 0 Twitter 1869389659777667539
achievelifesci avatar; Achieve Life Sciences @achievelifesci ·
13 Dec 1867570167997137077

According to @LungAssociation, when cigarettes burn, they release over 7,000 chemicals, including at least 69 known to cause cancer, many of which are toxic. Learn more about the ...health risks of smoking and take action to #QuitSmoking today: https://www.lung.org/quit-smoking/smoking-facts/whats-in-a-cigarette

Reply on Twitter 1867570167997137077 Retweet on Twitter 1867570167997137077 1 Like on Twitter 1867570167997137077 2 Twitter 1867570167997137077
Load More...

03.11.25

Press Release

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization…

/Read More

03.07.25

Press Release

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

SEATTLE and VANCOUVER, British Columbia, March 7, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will be presenting at the Barclays 27th Annual Global Healthcare…

/Read More

03.06.25

Press Release

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

SEATTLE and VANCOUVER, British Columbia, March 6, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide…

/Read More

02.11.25

Press Release

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

SEATTLE and VANCOUVER, British Columbia, February 11, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Rick Stewart, Chief Executive Officer of Achieve, will be presenting today at the virtual Oppenheimer 35th…

/Read More

02.10.25

Press Release

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, February 10, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation…

/Read More